Microbot Medical (NASDAQ:MBOT) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?

Microbot Medical Inc. (NASDAQ:MBOT) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.48 and traded as high as $2.78. Microbot Medical shares last traded at $2.73, with a volume of 1,282,595 shares traded.

Wall Street Analyst Weigh In

Several analysts have recently commented on MBOT shares. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm initiated coverage on Microbot Medical in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price target for the company. Finally, B. Riley Financial started coverage on Microbot Medical in a report on Tuesday, February 10th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Microbot Medical currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Microbot Medical Stock Performance

The firm has a market capitalization of $177.30 million, a PE ratio of -5.87 and a beta of 1.22. The business’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $2.47.

Institutional Trading of Microbot Medical

Several hedge funds have recently bought and sold shares of MBOT. Cornerstone Advisory LLC bought a new position in shares of Microbot Medical during the 3rd quarter valued at about $30,000. American Century Companies Inc. bought a new stake in shares of Microbot Medical in the second quarter worth about $32,000. Zacks Investment Management purchased a new stake in shares of Microbot Medical in the third quarter worth about $33,000. Man Group plc purchased a new stake in shares of Microbot Medical in the fourth quarter worth about $35,000. Finally, Squarepoint Ops LLC bought a new position in Microbot Medical during the third quarter valued at approximately $37,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.